Anestesia para portadores e indivíduos com risco de hipertermia maligna: relato de caso

Vládia Oliveira; Erick Freitas Curi; Antônio Roberto Carraretto

doi:10.47456/rbps.v26i1.41535

Authors

Vládia Oliveira Universidade Federal do Espírito Santo https://orcid.org/0009-0004-8305-6233
Erick Freitas Curi Universidade Federal do Espírito Santo - UFES https://orcid.org/0000-0003-1790-5685
Antônio Roberto Carraretto Universidade Federal do Espírito Santo - UFES

DOI:

https://doi.org/10.47456/rbps.v26i1.41535

Keywords:

Malignant hyperthermia, Halogenated, Succinylcholine, Pre-anesthetic preparation, Perioperative environment

Abstract

Introduction: Malignant hyperthermia (MH) is a pharmacogenetic clinical syndrome that, in its classic form, occurs during anesthesia with the use of drugs that trigger the MH crisis, such as halogenated drugs or the depolarizing neuromuscular blocker - succinylcholine. It was defined as an autosomal dominant inheritance, with more than 210 mutations in the ryanodine receptor (RYR1) in skeletal muscle. Case report: With the present case report and current bibliographic review, the objective is to describe the safe anesthetic technique used in a patient susceptible to MH and to make some considerations. The procedure was performed at the Hospital Universitário Cassiano Antônio Moraes (HUCAM/UFES), with adequate preparation of the perioperative environment. Conclusion: This article serves as a foundation for preparing a safer and more suitable environment for anesthetic management of patients susceptible to MH or with a confirmed diagnosis.

Downloads

Download data is not yet available.

Author Biographies

Erick Freitas Curi, Universidade Federal do Espírito Santo - UFES

Médico - Anestesiologista - TSA/SBA.
Doutor em Anestesiologia pela Faculdade de Medicina de Botucatu - UNESP
Professor do Departamento de Clínica Cirúrgica do Centro de Ciências da Saúde - UFES
Responsável pelo Centro de Ensino e Treinamento em Anestesiologia da AFECC/Hospital Santa Rita de Cássia

Antônio Roberto Carraretto, Universidade Federal do Espírito Santo - UFES

Malignant hyperthermia (MH) is a pharmacogenetic clinical syndrome that, in its classic form, occurs during anesthesia with the use of drugs that trigger the MH crisis, such as halogenated drugs or the depolarizing neuromuscular blocker - succinylcholine. It was defined as an autosomal dominant inheritance, with more than 210 mutations in the ryanodine receptor (RYR1) in skeletal muscle. With the present case report and current bibliographic review, the objective is to describe the safe anesthetic technique used in a patient susceptible to MH and to make some considerations. The procedure was performed at the Hospital Universitário Cassiano Antônio Moraes (HUCAM – UFES), with adequate preparation of the perioperative environment.

References

Cangiani LM, Carmona MJC, Ferez D, Bastos CO, Duarte LTD, Cangiani LH, Falcão LFR, Tardelli MA, Rodrigues RC. Tratado de anestesiologia. SAESP: Editora dos Editores; 2021 [cited 2023 May 31]. doi: 10.51864/9786586098327.

Miller RD, Cohen NH, Eriksson LI, Fleisher LA, Kronish JPW, Young WL. Miller Anestesia. 8. ed. Rio de Janeiro: Elsevier Editora Conhecimento sem Fronteiras; 2015.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare, 2015 ago;10(1). [internet]. [cited 2023 May 31]. doi: 10.1186/s13023-015-0310-1.

Gupta PK, Bilmen JG, Hopkins PM. Anesthetic management of a known or suspected malignant hyperthermia susceptible patient. BJA Educ, 2021 jun; 21(6):218-24. [internet]. [cited 2023 May 31]. doi: 10.1016/j.bjae.2021.01.003.

Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology, 2018 jan;128(1):159-67 [internet]. [cited 2023 May 31]. doi: 10.1097/aln.0000000000001877.

CEDHIMA. Centro de Estudo, Diagnóstico e Investigação de Hipertermia Maligna [internet]. [cited 2023 May 31]. http://cedhima.sites.unifesp.br/site/.

Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, Müller CR, Urwyler A. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth, 2015 out; 115(4):531-9 [internet]. [cited 2023 May 31]. doi: 10.1093/bja/aev225.

Glahn KP, Bendixen D, Girard T, Hopkins PM, Johannsen S, Rüffert H, Snoeck MM, Urwyler A. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth, 2020 ago;125(2):133-40 [internet]. [cited 2023 May 31]. doi: 10.1016/j.bja.2020.04.089.

MHAUS. Preparing the Anesthesia Machine for MHS Patients [internet]. Mhaus.org. 2016. [cited 2023 May 31]. https://www.mhaus.org/healthcare-professionals/be-prepared/preparing-the- anesthesia-machine/.

Silva WV, Ferez D, Mattos SLL, Nunes RR, Lima LHN, Lima RM. SAVA - Suporte avançado de vida em anestesia. 2. ed. Rio de Janeiro: Sociedade Brasileira de Anestesiologia; 2018. 434 p.